Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia

다국어 초록 (Multilingual Abstract)

Background: Trimethoprim/sufamethoxazole (TMP/SMX) is the recommended treatment for Pneumocystis jirovecii pneumonia (PCP). However, the efficacy and the safety of alternative salvage treatments are less guarauteed especially when patient experiences treatment failure and/or an adverse drug reactions (ADR). The purpose of this study is to recognize potential risk factors imitating successful treatment with TMP/SMX among PCP patients.
Materials and Methods: Ninety one adult patients diagnosed with PCP were included after searching electronical medical records from January 2013 through July 2015 at Asan Medical Center Seoul, Korea. We compared clinical characteristics and laboratory findings including bronchoalveolar lavage (BAL) fluid analysis in patients who experienced TMP/SMX treatment failure or ADR (the case group) versus those who did not (the control group).
Results: Among the enrolled PCP patients, 39 (42.9%) required salvage treatment owing to either treatment failure (28, 28.6%) and/or ADR (17, 18.7%). The BAL lymphocyte percentage (25% [IQR, 8–40%] vs. 47% [IQR, 15–62%]; P = 0.005) was lower in the case group. Diabetes mellitus (adjusted odds ratio [aOR] 4.98, 95% confidence interval [95% CI] 1.20–18.58), glomerular filtration rate ≤50 mL/min (aOR 4.48, 95% CI 1.08–18.66), and BAL lymphocyte percentage ≤45% (aOR 9.25, 95% CI 2.47–34.58) were independently associated with the case group in multivariate analysis.
Conclusion: This study suggests that BAL lymphocyte count may play some role during PCP treatment. Further studies should be followed to reveal what the role of BAL lymphocyte is in the PCP treatment.

참고문헌 (Reference)

1 Choi SH, "Viral infection in patients with severe pneumonia requiring intensive care unit admission" 186 : 325-332, 2012

2 Allegra CJ, "Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome" 317 : 978-985, 1987

3 Struijk GH, "Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation" 26 : 3391-3398, 2011

4 Walzer PD, "Priniciples and practice of infectious diseases" Elsevier 3016-3030, 2015

5 Fei MW, "Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study" 64 : 1070-1076, 2009

6 Catherinot E, "Pneumocystis jirovecii pneumonia" 24 : 107-138, 2010

7 Hashimoto K, "Pneumocystis jiroveci pneumonia in relation to cd4+ lymphocyte count in patients with b-cell non-hodgkin lymphoma treated with chemotherapy" 51 : 1816-1821, 2010

8 Kim T, "Outcomes of non-HIV-infected patients with Pneumocystis pneumonia and concomitant pulmonary cytomegalovirus infection" 44 : 670-677, 2012

9 Moon SM, "Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients" 55 : 4613-4618, 2011

10 Benfield TL, "Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with aids-associated Pneumocystis carinii pneumonia" 29 : 367-371, 1997

11 Duong T, "Laboratory and clinical predictors of disease progression following initiation of combination therapy in hiv-infected adults in Thailand" 7 : e43375-, 2012

12 Kim T, "Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review" 45 : 484-488, 2013

13 Fillatre P, "Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients" 127 : 1242.e11-1242.e17, 2014

14 Ruf B, "Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia" 10 : 207-210, 1991

15 Fauchier T, "Detection of Pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients" 54 : 1487-1495, 2016

16 Mitsides N, "Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients" 19 : 157-163, 2014

17 Helweg-Larsen J, "Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study" 64 : 1282-1290, 2009

18 Pfaller MA, "Clinical Mycology" Churchill Livingstone 385-401, 2009

19 Kim T, "Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia" 15 : 343-346, 2009

20 Toma E, "Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe pneumocystis carinii pneumonia in patients with aids: A multicenter, double-blind, randomized trial (CTN 004). CTN-PCP study group" 27 : 524-530, 1998

21 Shahrin L, "Characteristics and predictors of death among hospitalized HIV-infected patients in a low HIV prevalence country: Bangladesh" 9 : e113095-, 2014

22 Lee JY, "Cellular profiles of bronchoalveolar lavage fluid and their prognostic significance for non-HIV-infected patients with Pneumocystis jirovecii pneumonia" 53 : 1310-1316, 2015

23 Jensen BN, "Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis" 5 : 527-533, 1991

24 Deresinski SC, "Caspofungin" 36 : 1445-1457, 2003

25 Horan TC, "CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting" 36 : 309-332, 2008

26 Roblot F, "Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients" 21 : 523-531, 2002

27 Edwards IR, "Adverse drug reactions: definitions, diagnosis, and management" 356 : 1255-1259, 2000

28 Smego RA Jr, "A meta-analysis of salvage therapy for pneumocystis carinii pneumonia" 161 : 1529-1533, 2001